Plavix and PPIs

• Research type

  Research Study

• Full title

  Assessment of Platelet Inhibitory Response to Clopidogrel when Co-administered with a Proton Pump Inhibitor

• IRAS ID

  18549

• Sponsor organisation

  Papworth Hospital NHS Foundation Trust

• Eudract number

  2009-011543-40

• ISRCTN Number

  n.a

• Clinicaltrials.gov Identifier

  n.a

• Research summary

  National guidelines recommend the use of clopidogrel (Plavix) and aspirin following coronary syndromes, heart attacks and following coronary stent implantation to treat coronary narrowing??s. Both aspirin and clopidogrel thin the blood and prevent further coronary clot formation, but can also cause stomach irritation and ulcers. Frequently, physicians co-prescribe a proton pump inhibitor (PPI) to suppress acid production in the stomach and prevent stomach ulcers. However, certain PPIs (particularly omeprazole) are metabolised by the same liver enzyme that converts plavix into its active form. The efficacy of both plavix and PPI may be impaired by this co-prescription. We wish to further understand this interaction by assessing platelet function and gastrin levels (a surrogate for stomach acid suppression) following plavix coadministration with different PPIs and ranitidine, by recruiting patients undergoing elective stenting into a randomised controlled trial.

• REC name

  East of England - Cambridge South Research Ethics Committee

• REC reference

  09/H0305/37

• Date of REC Opinion

  9 Jul 2009

• REC opinion

  Further Information Favourable Opinion